SIGNATURES for Acorda_Therapeutics (ACOR)

close
close
close
close

Send us Feedback

Acorda Therapeutics (ACOR)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

ACOR » Topics » SIGNATURES

This excerpt taken from the ACOR 8-K filed Feb 22, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

February 22, 2010	By:	/s/ David Lawrence


		Name: David Lawrence
		Title: Chief Financial Officer

2

Exhibit Index

Exhibit No.		Description

99.1		Press Release dated February 22, 2010.

3

This excerpt taken from the ACOR 8-K filed Feb 3, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

February 3, 2010	By:	/s/ David Lawrence

		Name: David Lawrence
		Title: Chief Financial Officer

3

Exhibit Index

Exhibit No.		Description

99.1		Press Release dated February 3, 2010.

4

This excerpt taken from the ACOR 8-K filed Jan 29, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Acorda Therapeutics, Inc.

January 29, 2010		By:	/s/ David Lawrence

			Name: David Lawrence
			Title: Chief Financial Officer

2

This excerpt taken from the ACOR 8-K filed Jan 25, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

January 22, 2010	By:	/s/ David Lawrence

		Name: David Lawrence
		Title: Chief Financial Officer

3

Exhibit Index

Exhibit No.		Description

99.1		Press Release dated January 22, 2010.

4

This excerpt taken from the ACOR 8-K filed Jan 25, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

January 25, 2010	By:	/s/ David Lawrence

		Name: David Lawrence
		Title: Chief Financial Officer

2

Exhibit Index

Exhibit No.		Description

99.1		Press Release dated January 25, 2010.

3

This excerpt taken from the ACOR 8-K filed Jan 12, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

January 12, 2010	By:	/s/ David Lawrence

		Name: David Lawrence
		Title: Chief Financial Officer

3

This excerpt taken from the ACOR 8-K filed Nov 3, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

November 3, 2009	By:	/s/ David Lawrence

		Name: David Lawrence
		Title: Chief Financial Officer

3

Exhibit Index

Exhibit No.		Description

99.1		Press Release dated November 3, 2009

4

This excerpt taken from the ACOR 8-K filed Oct 22, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

October 22, 2009	By:	/s/ David Lawrence
		Name:	David Lawrence
		Title:	Chief Financial Officer

3

Exhibit Index

Exhibit No.		Description

99.1		Press Release dated October 22, 2009.

4

This excerpt taken from the ACOR 8-K filed Oct 15, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

October 14, 2009	By:	/s/ David Lawrence

		Name: David Lawrence
		Title: Chief Financial Officer

3

Exhibit Index

Exhibit No.		Description

99.1		Press Release dated October 14, 2009.

4

This excerpt taken from the ACOR 8-K filed Oct 14, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

October 14, 2009	By:	/s/ David Lawrence

		Name: David Lawrence
		Title: Chief Financial Officer

3

Exhibit Index

Exhibit No.		Description

99.1		Press Release dated October 14, 2009.

4

This excerpt taken from the ACOR 8-K filed Oct 9, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

October 9, 2009	By:	/s/ David Lawrence

		Name: David Lawrence
		Title: Chief Financial Officer

2

Exhibit Index

Exhibit No.		Description

99.1		Press Release dated October 9, 2009.

3

This excerpt taken from the ACOR 8-K filed Sep 15, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

September 15, 2009	By:	/s/ Jane Wasman

		Name: Jane Wasman
		Title: Executive Vice President, General Counsel and Corporate Secretary

2

Exhibit Index

Exhibit No.		Description

99.1		Press Release dated September 15, 2009.

3

This excerpt taken from the ACOR 8-K filed Sep 10, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

September 10, 2009	By:	/s/ David Lawrence

		Name: David Lawrence
		Title: Chief Financial Officer

3

Exhibit Index

Exhibit No.		Description

99.1		Press Release dated September 10, 2009.

4

RELATED TOPICS for ACOR:

"SIGNATURES" elsewhere:

AEterna Zentaris (AEZS)
Affymetrix (AFFX)
Alnylam Pharmaceuticals (ALNY)
Amylin Pharmaceuticals (AMLN)
Anika Therapeutics (ANIK)
American Oriental Bioengineering (AOB)
BioMarin Pharmaceutical (BMRN)
Cadence Pharmaceuticals (CADX)
Cambrex (CBM)
Cerus (CERS)
Charles River Laboratories International (CRL)
Crucell NV (CRXL)
Dendreon (DNDN)
Dyax (DYAX)
Emergent Biosolutions (EBS)
Enzon Pharmaceuticals (ENZN)
Exelixis (EXEL)
Halozyme Therapeutics (HALO)
Heska (HSKA)
Endo Pharmaceuticals Solutions Inc. (IDEV)
Illumina (ILMN)
Incyte (INCY)
Martek Biosciences (MATK)
Medivation (MDVN)
Medarex (MEDX)
Neurocrine Biosciences (NBIX)
NGEN, INC. (NGEN)
Transcept Pharmaceuticals Inc (NOVC)
NPS Pharmaceuticals (NPSP)
ARCA biopharma, Inc. (NUVO)
Obagi Medical Products (OMPI)
Omrix Biopharmaceuticals (OMRI)
ONYX Pharmaceuticals (ONXX)
Optimer Pharmaceuticals (OPTR)
OSI Pharmaceuticals (OSIP)
PerkinElmer (PKI)
Questcor Pharmaceuticals (QSC)
Regeneron Pharmaceuticals (REGN)
Repligen (RGEN)
Seattle Genetics (SGEN)
Sequenom (SQNM)
3SBio (SSRX)
Tongjitang Chinese Medicines Company (TCM)
Tercica (TRCA)
Targacept (TRGT)
ViroPharma (VPHM)
ZymoGenetics (ZGEN)

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

About | Blog | Press | Feedback | Help | Get involved

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs